These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2904696)

  • 21. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods.
    Kinon BJ; Jeste DV; Kollack-Walker S; Stauffer V; Liu-Seifert H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Sep; 28(6):985-96. PubMed ID: 15380859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum vitamin B6 in schizophrenic and schizoaffective patients with and without tardive dyskinesia.
    Miodownik C; Lerner V; Cohen H; Kotler M
    Clin Neuropharmacol; 2000; 23(4):212-5. PubMed ID: 11020126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vitamin E in the treatment of tardive dyskinesia.
    Boomershine KH; Shelton PS; Boomershine JE
    Ann Pharmacother; 1999 Nov; 33(11):1195-202. PubMed ID: 10573320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nifedipine in the treatment of tardive dyskinesia.
    Duncan E; Adler L; Angrist B; Rotrosen J
    J Clin Psychopharmacol; 1990 Dec; 10(6):414-6. PubMed ID: 1981070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients.
    Go CL; Rosales RL; Caraos RJ; Fernandez HH
    Parkinsonism Relat Disord; 2009 Nov; 15(9):655-9. PubMed ID: 19346155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tardive dyskinesia in 2 patients treated with ziprasidone.
    Ananth J; Burgoyne KS; Niz D; Smith M
    J Psychiatry Neurosci; 2004 Nov; 29(6):467-9. PubMed ID: 15644988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vitamin E in the treatment of tardive dyskinesia.
    Akhtar S; Jajor TR; Kumar S
    J Postgrad Med; 1993; 39(3):124-6. PubMed ID: 7914238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients.
    Chatterjee A; Chakos M; Koreen A; Geisler S; Sheitman B; Woerner M; Kane JM; Alvir J; Lieberman JA
    Am J Psychiatry; 1995 Dec; 152(12):1724-9. PubMed ID: 8526237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The current status of tardive dyskinesia.
    Sachdev PS
    Aust N Z J Psychiatry; 2000 Jun; 34(3):355-69. PubMed ID: 10881961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia.
    Sirota P; Mosheva T; Shabtay H; Giladi N; Korczyn AD
    Am J Psychiatry; 2000 Feb; 157(2):287-9. PubMed ID: 10671405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
    Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of negative symptoms with tardive dyskinesia in schizophrenic patients.
    Chiu H; Lau J; Lam L; Shum P
    Aust N Z J Psychiatry; 1993 Jun; 27(2):228-32. PubMed ID: 8103320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Buspirone in the treatment of tardive dyskinesia.
    Moss LE; Neppe VM; Drevets WC
    J Clin Psychopharmacol; 1993 Jun; 13(3):204-9. PubMed ID: 8102622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tardive dyskinesia and deficit schizophrenia.
    Telfer S; Shivashankar S; Krishnadas R; McCreadie RG; Kirkpatrick B
    Acta Psychiatr Scand; 2011 Nov; 124(5):357-62. PubMed ID: 21838740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation.
    Schultz SK; Miller DD; Arndt S; Ziebell S; Gupta S; Andreasen NC
    Biol Psychiatry; 1995 Dec; 38(11):713-9. PubMed ID: 8580223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vitamin E (alpha-tocopherol) in the treatment of tardive dyskinesia: a statistical meta-analysis.
    Barak Y; Swartz M; Shamir E; Stein D; Weizman A
    Ann Clin Psychiatry; 1998 Sep; 10(3):101-5. PubMed ID: 9781472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case series: spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia.
    Kumra S; Jacobsen LK; Lenane M; Smith A; Lee P; Malanga CJ; Karp BI; Hamburger S; Rapoport JL
    J Am Acad Child Adolesc Psychiatry; 1998 Feb; 37(2):221-7. PubMed ID: 9473920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
    Rajarethinam R; Dziuba J; Manji S; Pizzuti A; Lachover L; Keshavan M
    World J Biol Psychiatry; 2009; 10(4 Pt 2):416-9. PubMed ID: 19492247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.